Close Menu


The study will evaluate the emergence of biomarkers that are indicators for autoimmune diseases and assess these biomarkers in mild and moderate COVID-19 patients.

The company's fourth quarter revenues rose to $12.7 million, while full year revenues rose to $42 million.

DiaSorin got the green light for its Liaison Anti-HAV chemiluminescent immunoassay to detect total antibodies to the hepatitis A virus.

The kit helps in the qualitative and semi-quantitative determination of anti-double stranded DNA IgG antibodies with the use of fluorescence microscopy.

The company delivered about 28,600 of its Avise CTD tests with a quarterly retention rate of 99 percent among healthcare providers from the previous quarter.

The funding will be used to bring to market Oklahoma City-based Progentec's products for CLIA labs, as well as its digital technologies for managing lupus.

Following its IPO in September, the company is expanding its presence with increased product offerings in the pipeline and a renewed focus on reimbursement and R&D. 

The firm, which went public in September said that full-year 2019 revenues are expected to be between $40 million and $431 million.

The investment banks cited the company's access to proprietary technology and the potential $5 billion market for Exagen's testing options as reasons for its Outperform rating.  

Exagen, which develops and markets autoimmune tests, went public on the Nasdaq today and expects gross proceeds of $50.4 million from its IPO.